Quarterly report · Q2
9776.TEDINET S100PECX
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥10.0bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥19.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥9.6bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥493m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥777m | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥589m | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥821m | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥508m | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥717m | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥258m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.0bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥458m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥319m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥457m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥16.2bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥16.1bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥15.3bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.7bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥5.8bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥10.5bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥10.3bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥9.8bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.7bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.0bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.7bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.4bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥674m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.0bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥292m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥831m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥430m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥223m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥113m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥36m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥77.37 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥54.09 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥306.16 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥134.13 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥102.97 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 63.2% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.8% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥46m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥44m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥30m |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥371m |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥5.2bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥5.2bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥356m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥805m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥472m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥333m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥6m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥10.3bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥9.9bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥333m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥721m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥10.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥10.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥334m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥751m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-09-30 | ¥52m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥52m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥537,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-09-30 | ¥36m |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥580m |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥5.2bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥5.2bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥411m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥532m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥754m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥13m |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥10.3bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥9.5bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥754m |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥1.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥10.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥9.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥755m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥1.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 538
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of treasury stock fin cf | Prior1YTDDuration | -25917000 | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | -29214000 | JPY |
| Proceeds from share issuance to non controlling shareholders fin cf | Prior1YTDDuration | 220000000 | JPY |
| Proceeds from share issuance to non controlling shareholders fin cf | CurrentYTDDuration | － | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -78582000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -76984000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | 36212000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -223483000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 619531000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 742442000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 2350691000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 2980620000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 2970223000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 3723063000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YTDDuration | 223000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYTDDuration | － | JPY |
| Directors compensations sga | Prior1YTDDuration | 60930000 | JPY |
| Directors compensations sga | CurrentYTDDuration | 62968000 | JPY |
| Salaries and allowances sga | Prior1YTDDuration | 1048730000 | JPY |
| Salaries and allowances sga | CurrentYTDDuration | 1142427000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 178292000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 181448000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 11301000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 13642000 | JPY |
| Provision for directors retirement benefits sga | Prior1YTDDuration | 4628000 | JPY |
| Provision for directors retirement benefits sga | CurrentYTDDuration | 4784000 | JPY |
| Depreciation sga | Prior1YTDDuration | 70516000 | JPY |
| Depreciation sga | CurrentYTDDuration | 94084000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E04950-000ClinicalTestingBusinessReportableSegmentsMember | 3787939000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | 5195165000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | 531520000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 9514625000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 51747000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 9566372000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E04950-000ClinicalTestingBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | 753966000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 753966000 | JPY |
| Transactions with other segments | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 537000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 754503000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E04950-000ClinicalTestingBusinessReportableSegmentsMember | 3787939000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | 5195165000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | 1285486000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 10268591000 | JPY |
| Net sales | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 52284000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 10320875000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E04950-000ClinicalTestingBusinessReportableSegmentsMember | 579641000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | 410616000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | 13144000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 1003402000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |